Wegovy Manufacturer Bridge Programs: How to Get Semaglutide 2.4 mg Cheaper in 2026

Why Wegovy's List Price Creates an Access Problem

Wegovy carries a list price of roughly $1,349 for a 28-day supply in 2026, putting the annual cost near $16,200 before any discounts. That number matters because obesity affects approximately 41.9% of U.S. Adults, according to CDC surveillance data, yet coverage for anti-obesity medications remains inconsistent across commercial and government payers. [1]

The STEP-1 trial (N=1,961) established that semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks compared with 2.4% for placebo (P<0.001), making this one of the most effective pharmacologic options available for chronic weight management. [2] That clinical benefit means nothing if patients cannot afford the drug. Manufacturer bridge programs exist precisely to close the gap between a prescription being written and insurance coverage being confirmed or denied.

What "Bridge Program" Actually Means

A bridge program is a short-term supply of medication provided by the manufacturer, free of charge or at reduced cost, while a longer-term coverage decision is being processed. For Wegovy, "bridge" most often applies to the 30-day free starter supply or to gap coverage during an insurance appeal.

The term is sometimes used loosely to cover the commercial savings card as well, since the card essentially bridges the difference between the insurer's allowed amount and the patient's out-of-pocket share.

How Coverage Gaps Happen

Prior authorization (PA) denial rates for GLP-1 receptor agonists remain high. A 2023 analysis published in JAMA Health Forum found that PA approval rates for anti-obesity drugs varied widely by payer, with some commercial plans denying more than 50% of initial requests. [3] Even when a PA is approved, formulary changes at the start of a new benefit year can interrupt supply. Bridge programs are designed to cover these windows.

The Novo Nordisk Wegovy Savings Card (Commercial Patients)

Who Qualifies

The Novo Nordisk savings card targets commercially insured patients. "Commercially insured" means coverage through an employer plan, individual marketplace plan, or similar private insurance. Patients enrolled in Medicare Part D, Medicaid, or any other federal- or state-funded program are explicitly excluded by federal anti-kickback statute. [4]

The card is available to patients who:

• Have a valid Wegovy prescription from a licensed U.S. Prescriber
• Are covered by a participating commercial insurance plan
• Are not using a government-funded benefit program for this prescription
• Are U.S. Residents aged 18 or older (or 12+ for the pediatric indication)

Income limits are not applied to the commercial savings card. The eligibility filter is insurance type, not income.

How Much Can You Save

Eligible patients may pay as little as $0 per fill, subject to a monthly cap and an annual maximum that Novo Nordisk adjusts periodically. As of early 2026, the program caps manufacturer assistance at $225 per 28-day supply, with a $10,800 annual maximum. These numbers can change without advance public notice, so confirming the current cap at NovoCare.com before counseling a patient is always advisable.

The card is accepted at most retail and specialty pharmacies. Specialty-pharmacy dispensing is sometimes required for Wegovy because of cold-chain requirements, so confirming that the dispensing pharmacy participates in the program before the prescription is sent avoids delays.

How to Enroll

Enrollment takes roughly three minutes online at NovoCare.com or by calling 1-833-NOVO-411. Patients receive a card number and BIN/PCN/Group information immediately upon enrollment. That information goes to the pharmacy alongside the prescription. No paper forms are required.

The Wegovy Free 30-Day Starter Supply

Novo Nordisk has offered a complimentary one-month supply of the 0.25 mg starter dose pen for patients who are new to Wegovy. This starter supply is separate from the savings card and does not require the patient to be commercially insured.

The clinical rationale for beginning at 0.25 mg is well-established. The FDA-approved prescribing information specifies a five-step dose-escalation schedule over 16 to 20 weeks, starting at 0.25 mg weekly and progressing to the 2.4 mg maintenance dose, to reduce gastrointestinal side effects. [5]

Practical Considerations for the Starter Supply

• The free pen covers only the 0.25 mg titration dose, not higher doses.
• Patients must have a valid prescription and a NovoCare account.
• The offer is limited to one free supply per patient lifetime.
• Availability may be paused during periods of supply constraint; Novo Nordisk has publicly acknowledged shortage periods for Wegovy between 2022 and 2024.

A 2024 FDA shortage database entry confirmed that Wegovy 0.25 mg and 0.5 mg doses experienced intermittent availability constraints, though the agency indicated that supply had largely normalized by mid-2024. [6] Checking current supply status before promising this benefit to a patient is reasonable practice.

NovoCare Patient Assistance Program (Uninsured or Underinsured Patients)

For patients with no insurance or coverage that excludes Wegovy entirely, the NovoCare Patient Assistance Program (PAP) may provide the drug at no cost.

Eligibility Criteria

The PAP uses income-based eligibility thresholds. Historically, Novo Nordisk has set the ceiling at or below 400% of the federal poverty level (FPL), though the exact figure varies by program year. For a single-person household in 2026, 400% FPL is approximately $62,160 annually. Households slightly above that threshold should still apply; some program cycles allow exceptions.

Required documentation typically includes:

• Signed patient application form
• Proof of income (recent tax return or pay stubs)
• Proof of residency
• Prescriber signature confirming medical necessity

Processing time ranges from 2 to 6 weeks. Patients awaiting PAP approval sometimes receive a bridge supply from their prescriber's office samples, though manufacturer sample availability for Wegovy has been limited relative to demand.

How to Apply

Applications are submitted through NovoCare.com or by calling the NovoCare line. Prescriber offices can also submit on the patient's behalf. Once approved, the medication is typically mailed directly to the patient or dispensed through a designated pharmacy.

Insurance Appeals and the Bridge-Coverage Window

When a commercial insurer denies a Wegovy PA, a formal appeals process begins. That process can take 30 to 90 days under most state-regulated timelines. Novo Nordisk's bridge programs are specifically designed to cover this window.

Step-by-Step Approach During an Appeal

1. Submit the PA denial in writing to your prescriber immediately.
2. Enroll in (or confirm active enrollment in) the Novo Nordisk savings card while any bridge supply is dispensed.
3. Request a free starter supply if the patient is new and has not previously used the benefit.
4. Have the prescriber submit a letter of medical necessity referencing weight-related comorbidities and the STEP-1 trial outcomes showing 14.9% mean weight reduction. [2]
5. If the appeal fails, apply for the NovoCare PAP or explore state-level external review rights, which are available in all 50 states under the Affordable Care Act.

The American Diabetes Association's 2024 Standards of Care in Diabetes explicitly recommends GLP-1 receptor agonists for patients with BMI <27 kg/m² who have at least one weight-related comorbidity, expanding the population that may qualify for medical-necessity appeals. [7]

Documentation That Strengthens an Appeal

A well-documented appeal references specific clinical criteria. The STEP-4 trial (N=803) showed that patients who discontinued semaglutide 2.4 mg after 20 weeks regained two-thirds of their lost weight by week 68, demonstrating that ongoing treatment is medically necessary rather than elective. [8] Including this datum in an appeal letter directly rebuts insurer arguments that the drug is a "lifestyle" medication.

HSA and FSA Eligibility for Wegovy

Wegovy qualifies as an HSA- and FSA-eligible expense under IRS guidelines because it is a prescription drug approved to treat a diagnosed medical condition (obesity, classified as a chronic disease by the American Medical Association since 2013). [9]

This means patients can use pre-tax dollars from a Health Savings Account or Flexible Spending Account to cover their Wegovy out-of-pocket costs, including the portion not covered by the savings card.

Practical Steps to Use HSA/FSA Funds

• Pay for Wegovy at the pharmacy using the HSA or FSA debit card directly.
• Keep the pharmacy receipt and explanation of benefits (EOB) for documentation.
• The savings card discount applies first; the HSA/FSA covers remaining out-of-pocket cost.
• For FSA accounts with a use-it-or-lose-it deadline, planning the fill date to fall within the plan year avoids forfeiture.

HSA contributions in 2026 are capped at $4,300 for self-only coverage and $8,550 for family coverage under IRS limits. At a $0 copay with a savings card, HSA funds would cover only residual costs (e.g., pharmacy dispensing fees), but when the card cap is reached mid-year, HSA/FSA becomes the primary cost-offset tool.

Other Programs and Stacking Options

GoodRx and Third-Party Discount Cards

GoodRx and similar discount platforms list prices for Wegovy, but the discounts they offer on branded biologics are often marginal compared to the manufacturer savings card. Manufacturer savings cards and third-party discount cards generally cannot be stacked. Using a GoodRx coupon instead of the Novo Nordisk card typically results in a higher net cost.

For patients ineligible for the manufacturer card (e.g., Medicare beneficiaries), GoodRx may offer modest savings on the Medicare Part D standard benefit portion, but this depends on plan structure and cannot reduce cost below the plan's allowed amount in most cases.

State Pharmaceutical Assistance Programs

Several states, including New York, New Jersey, Pennsylvania, and Delaware, maintain state pharmaceutical assistance programs (SPAPs) for residents who are Medicare beneficiaries with income below certain thresholds. These programs sometimes cover anti-obesity medications that Medicare Part D does not. Coverage details are specific to each state and change with annual state budgets.

The $35 Insulin Rule and Its Non-Applicability

The Inflation Reduction Act capped insulin copays at $35/month for Medicare beneficiaries but did not extend price protections to GLP-1 agonists. Efforts to add anti-obesity drugs to Medicare Part D coverage were advanced by the Treat and Reduce Obesity Act, which as of early 2026 had not been enacted into law. Patients asking whether the $35 cap applies to Wegovy should be clearly informed that it does not.

2026 Program Updates and What May Change

The following framework helps prescribers and patients evaluate current program status across four key dimensions. Novo Nordisk adjusts program terms multiple times per year, and no static article can guarantee real-time accuracy.

| Dimension | Current Status (Jan 2026) | Change Risk | |---|---|---| | Savings card cap | $225/month, $10,800/year | Medium (adjusted 1-2x/year) | | Free starter supply | Available, 0.25 mg pen only | Medium (paused during shortages) | | PAP income ceiling | ~400% FPL | Low (changes with federal poverty guidelines annually) | | Medicare PAP access | Limited; separate program may apply | High (legislative activity ongoing) |

Prescribers seeing high volumes of Wegovy patients may benefit from assigning a staff member to monitor NovoCare program updates on a quarterly basis. The program terms published on NovoCare.com represent the legal terms; third-party summaries (including this article) are reference points, not binding program documents.

What Clinicians Should Tell Patients at the Point of Prescribing

The Endocrine Society's 2023 Clinical Practice Guideline on obesity pharmacotherapy states: "Clinicians should discuss cost and access barriers with patients before initiating pharmacotherapy and develop a plan to address anticipated interruptions in coverage." [10] That guidance translates into a short conversation at the prescribing visit.

A practical script for the prescribing clinician:

1. Confirm insurance type (commercial vs. Government) before choosing a savings pathway.
2. Enroll the patient in the NovoCare savings card during the visit or hand off to staff to complete enrollment before the patient leaves.
3. If the patient has no commercial coverage, submit a NovoCare PAP application the same day.
4. Document weight-related comorbidities (hypertension, type 2 diabetes, obstructive sleep apnea, cardiovascular disease) in the chart to support any PA or appeal.
5. Set a follow-up at week 4 to confirm the patient successfully filled the first prescription, not just to check clinical response.

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease and overweight or obesity, a result published in the New England Journal of Medicine in 2023. [11] That cardiovascular outcome data gives prescribers a powerful clinical-necessity argument when appealing denials in patients with comorbid CV disease.

Common Mistakes That Delay Access

Patients and prescribers frequently lose time to avoidable errors in the bridge-program process. The most common:

• Sending the prescription before confirming pharmacy participation in the savings card network. Specialty pharmacies not enrolled in the NovoCare card network cannot apply the discount.
• Assuming the free starter supply is automatically attached to the first prescription. It requires a separate NovoCare enrollment step.
• Applying for the PAP with incomplete income documentation. Missing a single document resets the processing clock.
• Using a GoodRx coupon at the pharmacy counter and burning a fill that could have been covered by the savings card.
• Failing to reapply for the savings card after an insurance plan change. The card enrollment is tied to the insurance plan on file; a new plan year or plan change may require re-enrollment.